Travere Therapeutics CEO Dube sells 243,735 shares

Q: How many TVTX shares did CEO Eric M. Dube sell, and at what prices?

Eric M. Dube reported sales of 128,065 shares at a weighted average $52.9672 per share, 37,270 at $54.1997, and 78,400 at $55.0179 on October 15, 2026. The reported sales were made pursuant to a written Rule 10b5-1(c) plan adopted June 16, 2026.

Q: What options did Travere Therapeutics CEO Eric M. Dube exercise?

On October 15, 2026, Dube exercised options to acquire 43,735 shares at $26.88 and 200,000 shares at $8.93. The options expire January 21, 2031, and January 31, 2034, respectively. The first option was fully vested and exercisable; one-fourth of the second vested January 31, 2025, with the remainder vesting in 36 equal monthly installments.

One option was fully vested and exercisable; the other vested one-fourth on January 31, 2025, with the remainder vesting in 36 equal monthly installments.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Travere Therapeutics, Inc. CEO Eric M. Dube exercised options on October 15, 2026, acquiring 43,735 shares at $26.88 and 200,000 shares at $8.93. He sold 128,065 shares at a weighted average price of $52.9672, 37,270 at $54.1997, and 78,400 at $55.0179. Each sale was made under a written Rule 10b5-1(c) plan adopted June 16, 2026. The options expire January 21, 2031, and January 31, 2034, respectively.

Insider Trade Summary 10b5-1

Exercise and Sale: 243,735 shares ($10.16M approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Dube Eric M

Role CHIEF EXECUTIVE OFFICER

Sold 243,735 shs ($13.12M)

Approx. gross sale proceeds $13.12M

Approx. exercise cost $2.96M

Approx. pre-tax spread $10.16M

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy) ^F5	43,735	$0.00	$0.00
Exercise	Employee stock option (right to buy) ^F6	200,000	$0.00	$0.00
Exercise	Common Stock	43,735	$26.88	$1.18M
Exercise	Common Stock	200,000	$8.93	$1.79M
Sale	Common Stock ^{F1, F2}	128,065	$52.9672	$6.78M
Sale	Common Stock ^{F1, F3}	37,270	$54.1997	$2.02M
Sale	Common Stock ^{F1, F4}	78,400	$55.0179	$4.31M

Holdings After Transaction: Employee stock option (right to buy) — 328,925 contracts (Direct); Common Stock — 432,886 shares (Direct)

Footnotes (6)

F1. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2. The weighted average sale price for the transaction reported was $52.9672, and the range of prices were between $52.63 and $53.6250. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3. The weighted average sale price for the transaction reported was $54.1997, and the range of prices were between $53.63 and $54.62. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4. The weighted average sale price for the transaction reported was $55.0179, and the range of prices were between $54.63 and $55.57. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5. The stock option is fully vested and exercisable.
F6. One-fourth of the shares subject to the stock option vested and became exercisable on January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

Key Figures

Option exercise: 43,735 shares at $26.88 per share Option exercise: 200,000 shares at $8.93 per share Sale at weighted average price: 128,065 shares at $52.9672 per share +2 more

5 metrics

Option exercise 43,735 shares at $26.88 per share October 15, 2026; option expires January 21, 2031.

Option exercise 200,000 shares at $8.93 per share October 15, 2026; option expires January 31, 2034.

Sale at weighted average price 128,065 shares at $52.9672 per share October 15, 2026.

Sale at weighted average price 37,270 shares at $54.1997 per share October 15, 2026.

Sale at weighted average price 78,400 shares at $55.0179 per share October 15, 2026.

Key Terms

Rule 10b5-1(c), weighted average sale price, fully vested and exercisable, equal monthly installments

4 terms

Rule 10b5-1(c) regulatory

"meeting the requirements of Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average sale price financial

"The weighted average sale price for the transaction reported"

fully vested and exercisable financial

"The stock option is fully vested and exercisable."

equal monthly installments financial

"the remaining shares vest in 36 equal monthly installments thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TVTX shares did CEO Eric M. Dube sell, and at what prices?

Eric M. Dube reported sales of 128,065 shares at a weighted average $52.9672 per share, 37,270 at $54.1997, and 78,400 at $55.0179 on October 15, 2026. The reported sales were made pursuant to a written Rule 10b5-1(c) plan adopted June 16, 2026.

What options did Travere Therapeutics CEO Eric M. Dube exercise?

On October 15, 2026, Dube exercised options to acquire 43,735 shares at $26.88 and 200,000 shares at $8.93. The options expire January 21, 2031, and January 31, 2034, respectively. The first option was fully vested and exercisable; one-fourth of the second vested January 31, 2025, with the remainder vesting in 36 equal monthly installments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/19/2026 - 04:05 PM EDT Accepted by SEC EDGAR 10/19/2026 - 04:05 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dube Eric M

(Last)

(First)

(Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/15/2026		M		43,735	A	$26.88	476,621	D
Common Stock	10/15/2026		M		200,000	A	$8.93	676,621	D
Common Stock	10/15/2026		S⁽¹⁾		128,065	D	$52.9672⁽²⁾	548,556	D
Common Stock	10/15/2026		S⁽¹⁾		37,270	D	$54.1997⁽³⁾	511,286	D
Common Stock	10/15/2026		S⁽¹⁾		78,400	D	$55.0179⁽⁴⁾	432,886	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee stock option (right to buy)	$26.88	10/15/2026		M			43,735	⁽⁵⁾	01/21/2031	Common Stock	43,735	$0	168,925	D
Employee stock option (right to buy)	$8.93	10/15/2026		M			200,000	⁽⁶⁾	01/31/2034	Common Stock	200,000	$0	160,000	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

2. The weighted average sale price for the transaction reported was $52.9672, and the range of prices were between $52.63 and $53.6250. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

3. The weighted average sale price for the transaction reported was $54.1997, and the range of prices were between $53.63 and $54.62. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

4. The weighted average sale price for the transaction reported was $55.0179, and the range of prices were between $54.63 and $55.57. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

5. The stock option is fully vested and exercisable.

6. One-fourth of the shares subject to the stock option vested and became exercisable on January 31, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR